Cardiology

New analyses from the MAESTRO program and real-world studies bolster the evidence base for the metabolic dysfunction-associated steatohepatitis therapy.

Researchers explore a variety of clinical services in addressing atrial fibrillation, cardiovascular risk, and social determinants of health.

A drug already used to protect the kidneys may now offer a broader shield.

Pharmacists help spot nonresponders, navigate accurate testing, and speed diagnosis.

Pharmacists close these gaps through screening and prevention for patients.

Based on data from the ADA’s 2026 Scientific Sessions, glucagon-like peptide-1s are continuing to revolutionize the cardiometabolic disease landscape.

Once-weekly mazdutide drives approximately 17% weight loss in Chinese adults with obesity, offering a dual GLP-1/glucagon metabolic option.

American College of Cardiology's new postpartum cardiovascular disease pathway urges early follow-up and tighter blood pressure goals.

Real-world data show GLP-1 drugs in type 1 diabetes cut heart and kidney risks, support weight loss, and appear safe with insulin adjustments.

FDA approves Baxfendy, a new oral aldosterone blocker, to help hard-to-control hypertension.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.

Through the lens of changes in medication adherence, researchers assessed differences in CVD-related emergency department visits and total cost of care.

Non-high-density lipoprotein cholesterol matters in type 2 diabetes care and can be managed with statins, combination therapy, and omega‑3s.

Community pharmacists weave brief lifestyle coaching and point-of-care testing into medication management, improving diabetes and hypertension outcomes.

This study indicates that stopping the medication is noninferior to continuing it indefinitely in terms of preventing death, recurrent heart attacks, or hospitalizations.

This benefit was primarily driven by significant reductions in nonfatal heart attacks and the need for revascularization procedures.

The study demonstrated that providing a combination of produce prescriptions, dietitian coaching, and artificial intelligence-optimized encouragement led to improved cardiovascular outcomes.

These guidelines serve as a comprehensive guideline that prioritizes earlier intervention through lifestyle optimization and lower treatment targets for those at highest risk.

New study links basal‑prandial insulin to healthier remnant cholesterol in type 2 diabetes, spotlighting hidden cardiovascular risk beyond low-density lipoprotein and A1c.

The health care landscape for metabolic liver disease is undergoing a shift, and pharmacists are being positioned at the forefront of this therapeutic revolution.

Episode 8 explores the real-world evidence, clinical trial data, and overall application of finerenone for pharmacists and their patients.

FDA expands lomitapide use to children 2 years and older, highlighting major low-density lipoprotein reductions.

Pharmacists help turn Food Is Medicine into covered care, linking heart patients to tailored meals, produce prescriptions, and easier chronic disease prevention.

In this episode, Natalie DiPietro Mager, PharmD, PhD, MPH, chats with Laney Poye, the director of marketing and communications at the Preeclampsia Foundation.

Phase 3 OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke by 26% on top of antiplatelets, without more major bleeding.